Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295217 · ClinicalTrials.gov registry record · Phase 3
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation
A Phase 3 study, sponsored by InSightec.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT00295217 is a Phase 3 study that has completed, run by InSightec. The registered enrollment target is 15 participants.
The verdict
NCT00295217, a Phase 3 study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this study is to validate the new ExAblate Application software V4.2 by developing additional data that shows the safety of this treatment. The ExAblate is intended to ablate uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure. Patients must have a uterine size of less than 24 weeks and not seeking treatment for reasons of improving fertility.
Interventions
- DEVICE ExAblate 2000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295217
The ClinicalTrials.gov registry entry for NCT00295217 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExAblate 2000 is the first listed.
NCT00295217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295217 about?
NCT00295217 is a clinical study titled "MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation". The goal of this study is to validate the new ExAblate Application software V4.2 by developing additional data that shows the safety of this treatment. The ExAblate is intended to ablate uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sp...
What is the current status of trial NCT00295217?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2006-02. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00295217?
The interventions under investigation include: ExAblate 2000 (DEVICE).
Who is sponsoring clinical trial NCT00295217?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.